Jan Westerink

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10302/publications.pdf

Version: 2024-02-01

112 papers	1,768 citations	304368 22 h-index	344852 36 g-index
112 all docs	112 docs citations	112 times ranked	3545 citing authors

#	Article	IF	Citations
1	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation, 2016, 134, 1419-1429.	1.6	183
2	Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovascular Diabetology, 2017, 16, 134.	2.7	89
3	Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3842-3853.	1.8	76
4	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes. Diabetes Care, 2018, 41, 1689-1695.	4.3	63
5	Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 220.	2.7	59
6	The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. European Heart Journal, 2019, 40, 3901-3909.	1.0	54
7	The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized, double-blind, placebo-controlled trial. American Journal of Clinical Nutrition, 2019, 110, 883-890.	2.2	53
8	Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 412-417.	1.1	45
9	Editor's Choice â€“ Cerebral Hyperperfusion Syndrome After Carotid Artery Stenting: A Systematic Review and Meta-analysis. European Journal of Vascular and Endovascular Surgery, 2018, 56, 322-333.	0.8	45
10	Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovascular Diabetology, 2011, 10, 13.	2.7	43
11	Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication. Journal of the American College of Cardiology, 2013, 62, 1834-1841.	1.2	42
12	Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. Blood, 2020, 135, 1377-1385.	0.6	39
13	High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis, 2013, 227, 118-124.	0.4	38
14	The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease. Diabetes Care, 2015, 38, 1930-1936.	4.3	35
15	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European Heart Journal, 2019, 40, 3771-3778a.	1.0	34
16	Intimal and medial calcification in relation to cardiovascular risk factors. PLoS ONE, 2020, 15, e0235228.	1.1	34
17	Associations Between Systolic Interarm Differences in Blood Pressure and Cardiovascular Disease Outcomes and Mortality. Hypertension, 2021, 77, 650-661.	1.3	34
18	Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy. Journal of Clinical Lipidology, 2017, 11, 12-23.e1.	0.6	33

#	Article	IF	Citations
19	HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1424-1430.	4.3	31
20	Inter-arm systolic blood pressure differences, relations with future vascular events and mortality in patients with and without manifest vascular disease. International Journal of Cardiology, 2017, 244, 271-276.	0.8	30
21	Arterial stiffness as a risk factor for cardiovascular events and allâ€cause mortality in people with Type 2 diabetes. Diabetic Medicine, 2019, 36, 1125-1132.	1.2	30
22	Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. International Journal of Cardiology, 2017, 248, 301-307.	0.8	27
23	Hemoglobin, hematocrit, and changes in cerebral blood flow: the Second Manifestations of ARTerial disease-Magnetic Resonance study. Neurobiology of Aging, 2015, 36, 1417-1423.	1.5	24
24	The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease. Atherosclerosis, 2020, 301, 37-43.	0.4	24
25	Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases. European Journal of Preventive Cardiology, 2012, 19, 864-873.	0.8	22
26	Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions. Journal of Vascular Surgery, 2017, 65, 1519-1527.e26.	0.6	22
27	Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease. International Journal of Obesity, 2015, 39, 265-269.	1.6	21
28	The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease. European Journal of Clinical Investigation, 2011, 41, 159-166.	1.7	20
29	Transcranial Doppler 24 Hours after Carotid Endarterectomy Accurately Identifies Patients Not at Risk of Cerebral Hyperperfusion Syndrome. European Journal of Vascular and Endovascular Surgery, 2019, 58, 320-327.	0.8	18
30	Effect of Type 2 Diabetes on Recurrent Major Cardiovascular Events for Patients With Symptomatic Vascular Disease at Different Locations. Diabetes Care, 2015, 38, 1528-1535.	4.3	17
31	Body Weight, Metabolic Dysfunction, and Risk of Type 2 Diabetes in Patients at High Risk for Cardiovascular Events or With Manifest Cardiovascular Disease: A Cohort Study. Diabetes Care, 2015, 38, 1945-1951.	4.3	17
32	The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. Cardiovascular Diabetology, 2016, 15, 101.	2.7	17
33	Effect of Statin Therapy on Incident Type 2 Diabetes Mellitus in Patients With Clinically Manifest Vascular Disease. American Journal of Cardiology, 2015, 115, 441-446.	0.7	16
34	Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. Diabetes Care, 2018, 41, 1244-1250.	4.3	16
35	Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial. Diabetes Care, 2019, 42, 1988-1994.	4.3	16
36	Tendon xanthomas: Not always familial hypercholesterolemia. Journal of Clinical Lipidology, 2016, 10, 1262-1265.	0.6	14

#	Article	IF	Citations
37	Anticoagulant bridging in left-sided mechanical heart valve patients. International Journal of Cardiology, 2017, 232, 121-126.	0.8	14
38	Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis. International Journal of Cardiology, 2018, 251, 96-102.	0.8	14
39	Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients. Diabetes and Metabolism, 2019, 45, 254-260.	1.4	14
40	Visceral Adipose Tissue and Different Measures of Adiposity in Different Severities of Diffuse Idiopathic Skeletal Hyperostosis. Journal of Personalized Medicine, 2021, 11, 663.	1.1	14
41	Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. European Journal of Internal Medicine, 2022, 100, 77-82.	1.0	14
42	Metabolic consequences of adipose tissue dysfunction and not adiposity per se increase the risk of cardiovascular events and mortality in patients with type 2 diabetes. International Journal of Cardiology, 2016, 222, 72-77.	0.8	13
43	Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and allâ€cause mortality: Findings from the SMART cohort. Diabetes, Obesity and Metabolism, 2019, 21, 1935-1943.	2.2	13
44	The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease. International Journal of Cardiology, 2021, 322, 251-257.	0.8	13
45	Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus. Acta Diabetologica, 2019, 56, 431-440.	1.2	12
46	Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. International Journal of Cardiology, 2021, 325, 140-148.	0.8	12
47	An Oral Mixed Fat Load Is Followed by a Modest Antiâ€inflammatory Adipocytokine Response in Overweight Patients with Metabolic Syndrome. Lipids, 2014, 49, 247-254.	0.7	11
48	Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health Research. BMC Public Health, 2022, 22, 660.	1.2	11
49	Chronic kidney disease and atrial fibrillation: A dangerous combination. PLoS ONE, 2022, 17, e0266046.	1.1	11
50	Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetes. European Journal of Endocrinology, 2021, 185, 831-840.	1.9	10
51	Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease. Atherosclerosis, 2015, 242, 605-610.	0.4	9
52	Intermittent pneumatic compression in combination with lowâ€molecular weight heparin in the prevention of venous thromboembolic events in esophageal cancer surgery. Journal of Surgical Oncology, 2017, 115, 181-185.	0.8	9
53	The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications. Cost Effectiveness and Resource Allocation, 2018, 16, 23.	0.6	9
54	Standardized reporting of co-morbidity outcome after bariatric surgery: low compliance with the ASMBS outcome reporting standards despite ease of use. Surgery for Obesity and Related Diseases, 2020, 16, 1673-1682.	1.0	9

#	Article	IF	Citations
55	Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. Heart, 2020, 106, 1686-1692.	1.2	9
56	Diffuse idiopathic skeletal hyperostosis is associated with incident stroke in patients with increased cardiovascular risk. Rheumatology, 2022, 61, 2867-2874.	0.9	9
57	Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk. Diabetes Care, 2022, 45, 1211-1218.	4.3	9
58	Postâ€thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study. Journal of Thrombosis and Haemostasis, 2022, 20, 1880-1886.	1.9	9
59	Combined use of polypill components in patients with type 2 diabetes mellitus. European Journal of Preventive Cardiology, 2018, 25, 1523-1531.	0.8	8
60	Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. JACC: CardioOncology, 2020, 2, 400-410.	1.7	8
61	Safety of using the combination of the Wells rule and Dâ€dimer test for excluding acute recurrent ipsilateral deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2020, 18, 2341-2348.	1.9	8
62	Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. Diabetes Research and Clinical Practice, 2022, 186, 109827.	1.1	8
63	Relation between adiposity and vascular events, malignancy and mortality in patients with stable cerebrovascular disease. International Journal of Obesity, 2017, 41, 1775-1781.	1.6	7
64	Outcomes of second opinions in general internal medicine. PLoS ONE, 2020, 15, e0236048.	1.1	7
65	Upper Extremity Deep Vein Thrombosis and Asymptomatic Vein Occlusion in Patients With Transvenous Leads: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 698336.	1.1	7
66	The relation between body iron stores and adipose tissue function in patients with manifest vascular disease. European Journal of Clinical Investigation, 2013, 43, 1240-1249.	1.7	6
67	Impaired Cytoskeletal and Membrane Biophysical Properties of Acanthocytes in Hypobetalipoproteinemia â€“ A Case Study. Frontiers in Physiology, 2021, 12, 638027.	1.3	6
68	Premature atherosclerosis, extremely low HDL-cholesterol and concurrent defects in APOA1 and ABCA1 genes: A family case report. International Journal of Cardiology, 2014, 177, e19-e21.	0.8	5
69	Association between bone metabolism regulators and arterial stiffness in type 2 diabetes patients. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 1245-1252.	1.1	5
70	Normal-range thyroid-stimulating hormone levels and cardiovascular events and mortality in type 2 diabetes. Diabetes Research and Clinical Practice, 2019, 157, 107880.	1.1	5
71	Apparent therapy-resistant hypertension as risk factor for the development of type 2 diabetes mellitus. Journal of Hypertension, 2020, 38, 45-51.	0.3	5
72	A Pathophysiological Perspective on the SARSâ€CoVâ€2 Coagulopathy. HemaSphere, 2020, 4, e457.	1.2	5

#	Article	IF	Citations
73	Overcoming Obstacles in Lipid-lowering Therapy in Patients with HIV - A Systematic Review of Current Evidence. AIDS Reviews, 2019, 20, 205-219.	0.5	4
74	Variation in perioperative cerebral and hemodynamic monitoring during carotid endarterectomy. Annals of Vascular Surgery, 2021, 77, 153-163.	0.4	4
75	Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 320-328.	2.2	3
76	Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis. Blood Advances, 2021, 5, 1369-1378.	2.5	3
77	Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. European Journal of Preventive Cardiology, 2021, , .	0.8	3
78	The ClearSight system for postoperative arterial blood pressure monitoring after carotid endarterectomy: a validation study. American Journal of Hypertension, 2021, , .	1.0	3
79	Research update for articles published in <scp>EJCI</scp> in 2011. European Journal of Clinical Investigation, 2013, 43, 1097-1110.	1.7	2
80	Relationship between recurrent miscarriage and early preterm delivery and recurrent events in patients with manifest vascular disease: The SMART study. European Journal of Preventive Cardiology, 2016, 23, 486-492.	0.8	2
81	Risk Factors for Recurrent Cardiovascular Events Before Age 65 Years or Within 2.5ÂYears of a Recent First Cardiovascular Event. American Journal of Cardiology, 2017, 120, 167-173.	0.7	2
82	2153The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease; a cohort study. European Heart Journal, 2019, 40, .	1.0	2
83	Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension. BMC Endocrine Disorders, 2020, 20, 56.	0.9	2
84	Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study. BMJ Open, 2021, 11, e038881.	0.8	2
85	End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study. Journal of Nephrology, 2021, 34, 1511-1520.	0.9	2
86	Pseudohypoparathyroidism mimicking cervical diffuse idiopathic skeletal hyperostosis with dysphagia: A case report and literature review. Bone Reports, 2021, 15, 101111.	0.2	2
87	Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease. PLoS ONE, 2022, 17, e0265050.	1.1	2
88	Lifestyle changes and kidney function: A 10â€year followâ€up study in patients with manifest cardiovascular disease. European Journal of Clinical Investigation, 2022, 52, e13814.	1.7	2
89	The Way to a Manâ€™s Stomach IsÂThrough His Heart?. Journal of the American College of Cardiology, 2013, 62, 761-762.	1.2	1
90	Research update for articles published in <scp>EJCI</scp> in 2013. European Journal of Clinical Investigation, 2015, 45, 1005-1016.	1.7	1

#	Article	IF	Citations
91	Letter by Westerink and Visseren Regarding Article, â€œEzetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of) Tj ETQq1 1 0.784314 rgBT /Overlock Multicenter Randomized Controlled Trialâ€• Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, e53.	1.1	1
92	2180Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European Heart Journal, 2019, 40, .	1.0	1
93	Bempedoic acid: Everything with a place and purpose. European Journal of Preventive Cardiology, 2020, , 2047487320929779.	0.8	1
94	The Impact of a Standardized Pre-visit Laboratory Testing Panel in the Internal Medicine Outpatient Clinic: a Controlled â€œOn-Offâ€•Trial. Journal of General Internal Medicine, 2021, 36, 1914-1920.	1.3	1
95	Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901â€“907. Diabetes Care, 2021, 44, e139-e139.	4.3	1
96	Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6. European Heart Journal, 2020, 41, .	1.0	1
97	Impact of a Patientâ€™s Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making. Journal of the American Heart Association, 2022, 11, e017605.	1.6	1
98	The relation between body iron stores and adipose tissue function in patients with manifest vascular disease. European Journal of Clinical Investigation, 2015, 45, 1127-1127.	1.7	0
99	Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424â€“1430. Diabetes Care, 2016, 39, e190-e191.	4.3	0
100	Reply to letter to the Editor â€œBridging anticoagulation in patients with mechanical heart valvesâ€• International Journal of Cardiology, 2017, 236, 399.	0.8	0
101	114Estimating individual cardiovascular disease risk reduction by blood pressure lowering in elderly patients: results from the HYVET study. European Heart Journal, 2018, 39, .	1.0	0
102	P4990Heterogeneity of treatment effects from an intensive lifestyle weight loss intervention on cardiovascular events in patients with type 2 diabetes: data from the Look AHEAD trial. European Heart Journal, 2019, 40, .	1.0	0
103	P1540Major adverse limb events (MALE) and the relation with classical risk factors in patients with symptomatic cardiovascular disease. European Heart Journal, 2019, 40, .	1.0	0
104	4943Remnant cholesterol increases the risk for recurrent vascular events independent of LDL-cholesterol in patients with clinical manifest vascular disease. European Heart Journal, 2019, 40, .	1.0	0
105	Applicability of Blood Pressureâ€“Lowering Drug Trials to Real-World Patients With Cardiovascular Disease. Hypertension, 2021, 77, 357-366.	1.3	0
106	FC 069CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION: A DANGEROUS COMBINATION. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
107	External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease. Cardiovascular Diabetology, 2021, 20, 181.	2.7	0
108	Distribution of cardiovascular risk in type 2 diabetes: results of an analysis using data from the CAPTURE study. European Heart Journal, 2021, 42, .	1.0	0

#	Article	IF	Citations
109	Redundant laboratory testing on referral from general practice to the outpatient clinic. BJGP Open, 2021, , BJGPO.2021.0134.	0.9	0
110	Prediction of 10-year and lifetime risk of cancer in individual patients with established cardiovascular disease, results from UCC-SMART and CANTOS. European Heart Journal, 2020, 41, .	1.0	0
111	External applicability of blood pressure-lowering drug trials to real-world patients with manifest cardiovascular disease. European Heart Journal, 2020, 41, .	1.0	0
112	Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease. European Heart Journal, 2020, 41, .	1.0	0